Omeros (OMER)
(Delayed Data from NSDQ)
$4.87 USD
-0.15 (-2.99%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $4.85 -0.02 (-0.41%) 7:58 PM ET
4-Sell of 5 4
C Value A Growth D Momentum B VGM
Brokerage Reports
0 items in cart
Omeros Corporation [OMER]
Reports for Purchase
Showing records 301 - 320 ( 423 total )
Company: Omeros Corporation
Industry: Medical - Products
Q1 Financials In-Line; We Project Financing Extends Runway Into Q4.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
In Addition To aHUS, OMS721 Could Become A Subcutaneous Treatment For AMD. We See Potential For Clinical Trials In 2014. Reiterate OUTPERFORM & $20 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Applied For Fast Track Designation For OMS824 In Huntington''s
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Applies For Orphan Drug Designation For OMS721 In aHUS; We Believe OMS721 Has Best-In-Class Potential; Reiterate OUTPERFORM And $20 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 15
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Preclinical Data Suggests Omeros'' GPR17 Antagonists May Reverse Multiple Sclerosis Degeneration; Reiterate OUTPERFORM and $20 FV.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
OMS824 Phase 1 Suggests Potency And Predictable Dosing For A Potential Blockbuster; Reiterate OUTPERFORM and $20 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
With Newly Defined MOA, PDE7 Inhibitor Set to Enter the Clinic in H2:13; Reiterate OUTPERFORM and $20 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Q4 Financials a Non-Event; Next - Phase 1 Data for OMS824 in Schizophrenia; Reiterate OUTPERFORM and $20 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Emerging Pharmaceuticals-March and Remaining 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of March 4
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Pipeline Progression: MASP-2 Inhibitor OMS721 Heading For The Clinic In 2013
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
February and 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
GPCR Program Unlocks Class B Targets To Provide Small Molecule Treatments For Oncology; Reiterate OUTPERFORM and $20 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
January and 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
We Recommend Buying OMER On Weakness As Mixed OMS103HP Phase 3 Results Still Warrant Continued Development
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Phase 1 OMS824, a PDE10 inhibitor, Data Supports Continued Development; Reiterate OUTPERFORM and $20 Fair Value.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Buy OMER; With Strengthening Fundamentals- Weakness Is Irrational, In Our View; We See Compelling Risk:Reward In Front Of Near- Term OMS103HP Ph3 Results
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Q3 Financials a Non-Event; We See Buying Opportunity In Front Of OMS103HP Phase 3 Data by Year-end; Reiterate OUTPERFORM and $20 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L